CEO Eliane Schutte will share the latest updates on Xeltis bio-restorative technology platform at the upcoming BioCapital Europe meeting, organized by healthcare investment firm LSP on 11 March.
“We have reached some important milestones across our portfolio, confirming the unique properties of our ETR platform,” commented Schutte. “We are now heading for three different restorative device indications in clinical settings, including one pivotal trial within the year. It is an exciting position to be in,” she added.
BioCapital Europe is Europe’s premier life sciences investment conference, offering VCs and Institutional Investors unique and timely access to around 40 exciting biotech, medtech and diagnostics companies from the Benelux and Europe.